
Dr Aguirre on Daraxonrasib Bringing RAS-Targeted Therapy to Pancreatic Cancer
Key Takeaways
- KRAS-driven pancreatic cancer has long lacked effective direct targeting; small-molecule RAS inhibitors now enable pharmacologic inactivation of this dominant oncogenic driver.
- Daraxonrasib acts via induced proximity, tethering cyclophilin A to RAS to suppress RAS(ON) signaling, supported by preclinical activity and strong phase 1 efficacy.
Andrew Aguirre, MD, PhD, explained how daraxonrasib, a molecular glue RAS inhibitor, nearly doubled overall survival in previously treated pancreatic cancer.
Daraxonrasib (Rasonque), a RAS(ON) inhibitor, is the most recent major advance in the treatment of pancreatic cancer, according to Andrew Aguirre, MD, PhD, who discusses the agent’s development and phase 3 results in an interview.
KRAS is mutated in the vast majority of pancreatic cancers and has been recognized for decades as the major driver of the disease, but the protein proved difficult to target with drugs, Aguirre said. KRAS inhibitors, which are small molecules that bind to the protein and inactivate it, are now available.
“Those drugs have really shown amazing efficacy in patients,” says Aguirre, associate professor of medicine at Harvard Medical School and associate director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute in Boston, Massachusetts.
Aguirre describes daraxonrasib as a molecular glue. The drug takes cyclophilin A, a protein that ordinarily does not interact with RAS, and binds it to the RAS protein, inactivating the oncogenic driver in pancreatic cancer cells. Preclinical data suggested the agent would be active in the disease, he said, and a phase 1 clinical trial subsequently read out with impressive efficacy in pancreatic cancer.
A large randomized controlled trial,
In the overall population, median OS was 13.2 months (95% CI, 10.0–not estimable) with daraxonrasib vs 6.7 months (95% CI, 5.8–8.0) with standard-of-care chemotherapy (HR, 0.40; 95% CI, 0.30–0.53; P < .0001).2 Median progression-free survival was 7.2 months (95% CI, 5.7–7.5) vs 3.6 months (95% CI, 2.9–4.2; HR, 0.49; 95% CI, 0.38–0.64; P < .0001), and the objective response rate was 30% (95% CI, 25%–36%) vs 11% (95% CI, 7%–15%; P < .0001).2
The
“RAS inhibition nearly doubled overall survival compared to second-line chemotherapy alone,” says Aguirre.
REFERENCES
1. Wolpin BM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): primary and final analysis from the phase 3 RASolute 302 study. J Clin Oncol. 2026;44(suppl 17):LBA5. doi:10.1200/JCO.2026.44.17_suppl.LBA5
2. FDA approves first in class targeted therapy for metastatic pancreatic cancer. FDA August 26, 2026. Accessed November 17, 2026. https://tinyurl.com/457vwtek
Related to this article








